A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Phase 2 Completed 87 enrolled Vertex Pharmaceuticals Incorporated

RandomizedSequentialQuadruple-blindTreatment

The purpose of this study is to evaluate the safety, tolerability and efficacy of VX-121 combination therapy in subjects with cystic fibrosis (CF).

Evaluation	Drug	Modality	Dose	Route
Comparator	IVA	Unknown	150 mg	Oral
Comparator	TEZ/IVA	Unknown	—	Oral
Subject	Vanzacaftor	Small molecule	5 mg	Oral
Subject	Vanzacaftor	Small molecule	10 mg	Oral
Subject	Vanzacaftor	Small molecule	20 mg	Oral
Subject	deutivacaftor	Unknown	150 mg	Oral
Background	TEZ	Unknown	100 mg	Oral